Abstract:
PURPOSE: A pharmaceutical composition containing pyridazinone derivatives is provided to effectively suppress cancer cell growth and to prevent or treat benign prostatic hyperplasia, acne, sterility, or male pattern baldness. CONSTITUTION: A pyridazinone derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating androgen-associated diseases contains the derivatives of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is administered in the form of a tablet, pill, soft/hard capsule, liquid, suspension, emulsion, syrup, granule, elixir, or troche by oral administration and hypodermic injection, intravenous injection, intramuscular injection by parenteral administration.
Abstract:
PURPOSE: A benzamide derivative, a manufacturing method thereof, and a prevention and curing pharmaceutical composition containing thereof are provided to prevent the loss of bones, and to prevent the bone diseases including osteoporosis and periodontal disease. CONSTITUTION: A manufacturing method of a benzamide derivative comprises the following steps: reacting a compound marked with chemical formula 2, with a compound marked with chemical formula 3, to obtain a compound marked with chemical formula 4; hydrolyzing the compound marked with the chemical formula 4, to obtain a compound marked with chemical formula 5; and couple-reacting the compound marked with the chemical formula 5, to obtain the benzamide derivative marked with chemical formula 1.
Abstract:
PURPOSE: A pharmaceutical composition for promoting osteoblast containing physcion glucopyranoside or physcion is provided to promote mineralize mesenchymal stem cell and prevent and treat disease and symptom such as osteoporosis and fracture. CONSTITUTION: A pharmaceutical composition for preventing or treating bone disease contains 0.0001~50 weight% of physcion-8-O-β-D-glucopyranoside of chemical formula 1 or physcion of chemical formula 2 as an active ingredient. Bone disease includes fracture, osteoporosis, periodontal disease and bone growth failure. The physcion-8-O-β-D-glucopyranoside is administered in 1~150mg/kg per day. The physcion-8-O-β-D-glucopyranoside or physcion is isolated from Polygonum multiflorum.
Abstract:
A pharmaceutical composition for preventing and treating bone disease is provided to decrease bone resorption and enhance bone formation by using a baicalein. A pharmaceutical composition for preventing and treating bone disease comprises a baicalein of the chemical formula 1 as an active ingredient. The bone disease is selected from osteoporosis, fracture, periodontal disease and bone growth failure. The baicalein is contained in the amount of 0.0001-50 weight% based on total weight. The composition further comprises a pharmaceutically allowable additive.
Abstract:
본 발명은 광학활성 α-플루오로메틸 프로파길 알콜 유도체의 제조방법에 관한 것으로, 캔디다 안타르크티카( Candida antarctica ) 또는 뮤코 미에헤이( Mucor miehei ) 유래의 리파제 촉매 존재하에, 라세믹 α-플루오로메틸 프로파길 알콜 유도체를 비닐 알카노에이트와 반응시켜 입체선택적으로 에스테르화 반응을 수행함으로써 (-)-형태의 광학활성체와 에스테르 유도체를 얻는 후, 이 에스테르 유도체를 가수분해하여 (+)-형태의 광학활성체를 얻는 것을 특징으로 한다. 이러한 본 발명의 방법에 의하면, 목적하는 광학활성 α-플루오로메틸 프로파길 알콜 유도체를 라세믹 원료화합물로부터 용이하게 얻을 수 있으며, 수득된 광학활성 화합물은 최대 99% ee 이상의 높은 광학순도를 갖는다.
Abstract:
Antifungal azole compounds and a process for preparing the same compounds are provided to improve antifungal activity, especially against fluconazole-resistant Candida albicans, and minimize liver toxicity caused by long-term dosage by enhancing safety of the compounds against the human CytP450 enzyme. The antifungal triazole compounds represented by the formula(1), or pharmaceutically acceptable salts or isomers thereof are provided, wherein R is hydrogen or trifluoromethyl(CF3) group, and X is hydrogen or at least one halogen, C1-4 alkyl group, C1-4 haloalkyl group, C1-4 alkoxy group or dioxymethylene group. The antifungal triazole compounds represented by the formula(1) are prepared by reacting alcohol compounds represented by the formula(2) with styrene compounds represented by the formula(3) in the presence of base in organic solvent.
Abstract:
본 발명은 p53 종양 억제단백질(tumor suppressor)과 제1 형광단백질의 융합단백질 및 제2 형광단백질을 발현하는 형질전환 세포주, 및 이를 이용하여 p53 종양 억제단백질의 활성에 관여하는 물질을 검색하는 방법에 관한 것으로, 구체적으로 5'에서 3' 방향으로 143번째 아미노산인 발린이 알라닌으로 치환된 비활성 p53 종양 억제단백질 돌연변이 유전자; 상기 유전자에 융합된 제1 형광단백질 유전자; IRES(internal ribosome entry site) 리보솜 결합 염기서열; 및 제2 형광단백질 유전자를 포함하고, 이들의 발현이 하나의 프로모터에 의해 조절되는 재조합 발현벡터; 상기 발현벡터가 안정적으로 도입된 형질전환 세포주; 및 상기 형질전환 세포주를 이용하여 p53 종양 억제단백질의 활성을 증가시키거나 억제하는 물질을 검색하는 방법에 관한 것이다. 본 발명에 따른 재조합 발현벡터 및 형질전환 세포주는 p53 종양 억제단백질의 활성과 관련된 물질을 검색하기 위한 바이오센서로서 항암제, 항암치료 보조제 및 퇴행성 질환 관련 치료제를 스크리닝하는데 유용하게 사용될 수 있다.
Abstract:
본 발명은 올레핀의 알파 위치에 트리뷰틸틴기를 갖는 비닐포스포네이트의 제조 방법에 관한 것으로, 구체적으로는 아세틸렌일포스포네이트를 트리뷰틸틴하이드라이드와 반응시켜 올레핀의 알파 위치에 트리뷰틸틴기가 치환된 하기 화학식 1의 비닐포스포네이트를 제조하는 방법은 합성 방법이 매우 간편하여 이 트리뷰틸틴기의 반응성을 이용하여 다양한 화합물을 제조하는데 유용하게 활용될 수 있다.